AmnioAMP Application Protocol: Step-by-Step Guide for Wound Care Teams

A practical, evidence-informed workflow for wound-bed preparation, graft sizing, application technique, and follow-up care when using amniotic membrane allografts in the clinical setting.

Published 24 May 2026 • Clinical Protocol • NextGen Biologics

Overview

Amniotic membrane allografts have become a standard adjunct in advanced wound care for chronic wounds that fail to respond to conventional therapy. The application protocol is straightforward, but execution details matter: wound-bed preparation determines graft take, product format (cryopreserved versus dehydrated) changes handling steps, and secondary dressing selection affects graft stability between visits.

This guide outlines a general best-practice protocol for applying amniotic membrane allografts in wound care. It is intended for wound care nurses, surgical techs, and procurement staff evaluating product usability. Clinicians should follow the manufacturer's current Instructions for Use (IFU) for product-specific parameters.

Regulatory context. Amniotic membrane products discussed here are regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under FDA 21 CFR Part 1271 and section 361 of the Public Health Service Act, provided they meet criteria for homologous use and minimal manipulation.

Step 1: Wound-Bed Preparation

Graft adherence and viability depend on a clean, well-vascularized wound bed. Incomplete preparation is the most common reason for poor outcomes with skin substitutes of any class.

Debridement

Remove necrotic tissue, slough, and non-viable eschar by sharp, enzymatic, autolytic, or mechanical means per institutional protocol. The Wound, Ostomy and Continence Nurses (WOCN) Society guidelines emphasize that adequate debridement precedes any advanced dressing or skin substitute application. [1]

Biofilm disruption

Chronic wounds harbor polymicrobial biofilms that impede healing. Consider adjunctive biofilm-disruption strategies (sharp debridement, topical antiseptics, or low-frequency ultrasound) prior to graft placement. The International Wound Infection Institute (IWII) 2023 consensus identifies biofilm as a primary driver of wound chronicity and recommends active disruption before applying biologics. [2]

Hemostasis

Ensure the wound bed is free of active bleeding. Excessive blood or serous fluid beneath the graft creates a fluid interface that prevents contact with the wound bed. Light pressure with gauze is usually sufficient; avoid cautery or chemical hemostasis directly on the application surface unless clinically necessary.

Periwound skin

Clean and dry the periwound area. Apply a skin protectant if maceration is present. The graft should overlap onto intact periwound skin by 1 to 2 mm for secure anchoring.

Step 2: Wound Measurement and Graft Sizing

Measure the wound at its longest length and widest width, recording the dimensions in the patient chart. For irregular wounds, trace the perimeter onto a transparent grid film or photograph with a calibrated ruler in frame.

Select a graft size that covers the entire wound bed with a 1 to 2 mm overlap onto the periwound skin. If the wound is larger than a single graft sheet, multiple grafts may be applied with slight overlap (2 to 3 mm) at the seams. Do not stretch the graft to fit; cutting to size with sterile scissors is preferred.

Documentation note. Record pre-application wound dimensions, exudate level, odor, periwound condition, and any signs of infection. Photographic documentation is recommended for medicolegal and payer-review purposes.

Step 3: Product Handling and Preparation

Handling steps differ between cryopreserved and dehydrated amniotic membrane products. Verify the product label and IFU before opening the package.

Step Cryopreserved Dehydrated
Storage −80°C freezer or liquid nitrogen; maintain cold chain Room temperature; no cold chain required
Pre-application prep Thaw in sterile saline at room temperature for 10 to 15 minutes per IFU Apply dry directly to wound, or hydrate briefly in sterile saline per IFU
Orientation Apply with basement membrane side (stroma side) facing the wound bed per IFU Apply per IFU; some products are single-layer and orientation-independent
Working time (opened) Use promptly after thawing; do not refreeze Longer working window; reseal unused portions per IFU if applicable

Structural studies have documented that cryopreservation retains native extracellular matrix architecture and higher levels of high-molecular-weight hyaluronic acid and heavy chain-HA complexes compared to terminally sterilized dehydrated products. [3] Aseptically processed dehydrated products (without terminal irradiation) retain more native structure than their gamma-irradiated counterparts. [3, 4] These differences influence handling but do not establish clinical superiority in head-to-head trials.

Step 4: Application Technique

  1. Don sterile gloves. Maintain aseptic technique throughout.
  2. Position the graft. Lay the graft onto the wound bed with the appropriate surface facing down. Avoid folding or wrinkling.
  3. Secure contact. Gently smooth the graft from the center outward to eliminate air pockets and ensure full contact with the wound bed. The graft should lie flat against the tissue without tension.
  4. Periwound overlap. Ensure 1 to 2 mm of graft extends onto intact periwound skin. This overlap helps prevent edge lifting and fluid accumulation beneath the graft.
  5. Moisten if needed. For dehydrated grafts applied dry, the wound exudate will hydrate the graft in situ. For cryopreserved grafts, a light saline mist over the surface can prevent desiccation before the secondary dressing is applied.

Do not apply topical antibiotics, antiseptics, or other wound-care products directly beneath the graft unless specified in the IFU. These may interfere with graft adherence or alter the biological activity of the membrane.

Step 5: Secondary Dressing Selection

The secondary dressing protects the graft, manages exudate, and maintains a moist wound environment. Selection depends on exudate level, wound location, and patient mobility.

Exudate Level Recommended Secondary Dressing Rationale
Low Non-adherent silicone contact layer + gauze Prevents graft disruption during dressing changes; maintains moisture
Moderate Foam dressing or hydrofiber Absorbs exudate without macerating periwound skin
High Alginate or superabsorbent polymer dressing Manages heavy exudate; change every 24 to 48 hours
Offloading (foot/heel) Total contact cast or removable boot Reduces shear and pressure on the graft site

Secure the dressing with tape, wrap, or tubular netting. Avoid adhesive tape directly on the graft or periwound skin if the patient has fragile skin or known adhesive sensitivity.

Step 6: Follow-Up Schedule and Reapplication

Follow-up intervals vary by wound type, exudate level, and institutional protocol. Typical schedules for amniotic membrane allografts in chronic wounds range from weekly to every two weeks.

A multicenter RCT of dehydrated human amnion/chorion membrane in venous leg ulcers demonstrated that both weekly and biweekly application schedules achieved superior closure rates compared to standard of care alone, with no significant difference between frequencies. [4] This suggests flexibility in scheduling based on clinic capacity and patient logistics.

Contraindications and Precautions

Amniotic membrane allografts are generally well tolerated, but certain conditions warrant caution or deferral:

Documentation Requirements

Thorough documentation supports clinical continuity, quality assurance, and payer reimbursement. At minimum, record the following at each visit:

For CMS reimbursement under the Physician Fee Schedule, skin substitute application requires documentation of medical necessity, prior standard-of-care failure, and wound characteristics consistent with covered indications. [5]

Summary

The application of amniotic membrane allografts follows a six-step workflow: wound-bed preparation, measurement and sizing, product-specific handling, graft placement, secondary dressing selection, and scheduled follow-up with reapplication as indicated. Cryopreserved and dehydrated products differ in storage, preparation time, and handling details, but both formats have demonstrated clinical activity as adjuncts to standard of care in published trials.

Success depends less on the product format and more on disciplined wound-bed preparation, appropriate patient selection, and consistent follow-up. Teams that standardize this protocol see more predictable outcomes and fewer graft failures.

Evaluate AmnioAMP for Your Wound Center

Request samples of AmnioAMP or Rampart and speak with our clinical support team about protocol integration.

Request Samples

References

  1. Wound, Ostomy and Continence Nurses Society. Guidelines for the management of wounds in patients with lower-extremity arterial disease. J Wound Ostomy Continence Nurs. 2022;49(2):123-136. doi:10.1097/WON.0000000000000897
  2. International Wound Infection Institute. Wound infection in clinical practice: IWII consensus document. 2023 Update. Wounds International. 2023. Available at: https://woundsinternational.com
  3. Cooke M, Tan EK, Mandrycky C, et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care. 2014;23(10):465-474. doi:10.12968/jowc.2014.23.10.465
  4. Serena TE, Orgill DP, Armstrong DG, et al. A multicenter, randomized, controlled, clinical trial evaluating dehydrated human amniotic membrane in the treatment of venous leg ulcers. Plast Reconstr Surg. 2022;150(5):1128-1136. doi:10.1097/PRS.0000000000009650 (PMCID: PMC9586828)
  5. Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule 2026: Skin substitute application coding and reimbursement guidance. Available at: https://www.cms.gov/medicare/payment/fee-schedules

Disclaimer: This article presents general best-practice guidance for the application of amniotic membrane allografts in wound care. It does not replace the manufacturer's current Instructions for Use (IFU) or institutional clinical protocols. Clinicians should follow the product-specific IFU and their facility's standard operating procedures. This content is for educational purposes and does not constitute medical advice, product endorsement, or a guarantee of clinical outcomes. NextGen Biologics is a distributor of human tissue products regulated under FDA 21 CFR Part 1271.